Top Page
Impedimed Limited
(Sydney:IPD)
Impedimed Limited (IPD) vs. iShares MSCI Australia ETF (EWA)
Impedimed Limited Business Overview & Revenue Model
Impedimed Limited Earnings Call Summary
Impedimed Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.32M | 11.34M | 10.57M | 8.41M | 5.74M |
| Gross Profit | 9.01M | -13.65M | -13.35M | -12.20M | -12.89M |
| EBITDA | -22.05M | -20.49M | -18.65M | -20.70M | -24.07M |
| Net Income | -19.79M | -20.52M | -19.87M | -20.71M | -21.38M |
Balance Sheet | |||||
| Total Assets | 46.99M | 68.74M | 58.70M | 34.20M | 33.06M |
| Cash, Cash Equivalents and Short-Term Investments | 24.63M | 45.71M | 40.73M | 19.68M | 19.66M |
| Total Debt | 1.14M | 1.45M | 170.00K | 474.00K | 871.00K |
| Total Liabilities | 6.24M | 7.86M | 7.66M | 8.69M | 5.70M |
| Stockholders Equity | 40.74M | 60.88M | 51.04M | 25.51M | 27.36M |
Cash Flow | |||||
| Free Cash Flow | -20.89M | -24.09M | -20.89M | -15.71M | -21.38M |
| Operating Cash Flow | -17.79M | -18.05M | -15.66M | -13.26M | -19.22M |
| Investing Cash Flow | -3.10M | -6.04M | -5.22M | -2.46M | -2.16M |
| Financing Cash Flow | -481.00K | 27.93M | 39.92M | 16.47M | 30.16M |
Impedimed Limited Technical Analysis
Impedimed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $95.40M | ― | -51.08% | ― | 10.22% | -2.94% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
| ― | $26.50M | ― | -50.50% | ― | ― | ― | |
54 Neutral | AU$60.55M | ― | -8.08% | ― | -5.62% | -225.71% | |
49 Neutral | AU$55.38M | ― | -135.33% | ― | -27.58% | 33.69% | |
46 Neutral | AU$148.80M | ― | -58.61% | ― | ― | -74.88% | |
41 Neutral | AU$115.58M | ― | -35.20% | ― | 4.68% | -155.42% |
Impedimed Limited Corporate Events
ImpediMed Limited announced a change in the director’s interest, with Mr. Andrew Grant acquiring 268,169 ordinary shares, increasing his total to 2,774,399 shares. This acquisition was made through the issuance of shares in lieu of 30% of director fees for the quarter ended June 30, 2025, reflecting a strategic decision to align director compensation with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced a change in the director’s interest notice, involving Ms. Christine Emmanuel-Donnelly. The change reflects the issuance of 474,084 ordinary shares to IDEAHL Pty Ltd, a trust where Ms. Emmanuel-Donnelly is a director and beneficiary, as part of her director fees for the quarter ended June 30, 2025. This move indicates a strategic decision to compensate directors through equity, potentially aligning their interests with those of shareholders and impacting the company’s financial structure.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited announced a change in the director’s interest notice, specifically involving Ms. Janelle Delaney. The change reflects the acquisition of 268,169 ordinary shares as part of a compensation arrangement, where shares were issued in lieu of 30% of director fees for the quarter ending June 30, 2025. This adjustment in shareholding could impact the company’s governance and stakeholder interests, as it aligns director compensation with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced a change in the director’s interest, as Fiona Bones acquired an additional 268,169 ordinary shares, increasing her total holdings to 1,774,399 shares. This acquisition was part of a compensation arrangement where shares were issued in lieu of 30% of her director fees for the quarter ended June 30, 2025, reflecting a strategic approach to align management interests with shareholder value.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.15 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has announced the issuance of 1,100,901 fully paid ordinary shares to its executives as part of their remuneration for the quarter ending June 30, 2025. This move, under the Executive Share Plan, reflects the company’s strategy to align executive compensation with company performance, potentially impacting its financial structure and stakeholder interests.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced the issuance of 1,278,591 ordinary fully paid shares to non-executive directors as part of their Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending June 30, 2025. This move is part of the company’s ongoing strategy to align the interests of its directors with those of its shareholders, potentially enhancing governance and stakeholder confidence.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited, a company listed on the Australian Securities Exchange, has released a presentation to be delivered to investors and analysts. This announcement signifies the company’s ongoing engagement with its stakeholders and may provide insights into its financial performance and strategic direction for the fourth quarter of fiscal year 2025.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited reported a record Total Contract Value (TCV) of $6.3 million for its SOZO Core Business in Q4 FY25, driven by enhanced sales strategies and leadership. The company sold 44 SOZO units in the US, including a significant contract with Legacy Health, while no units were sold internationally due to distributor restocking schedules. Despite a slight revenue decline to $3.3 million, the company maintained strong annual recurring revenue growth and reduced its cash cost base by 16% compared to FY24. ImpediMed’s financial position remains robust with a cash balance of $22.2 million, positioning it well for future growth.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced the issuance of 6,245,935 unquoted securities, specifically IPDAB warrants, as part of a previously disclosed transaction. This issuance, which is not intended to be quoted on the ASX, may impact the company’s financial structure and provide additional resources for its strategic initiatives, potentially influencing its market position and stakeholder interests.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has announced the release of its Appendix 4C Quarterly Cash Flow Report for the period ending 30 June 2025, scheduled for 31 July 2025. The company will host an investor conference call on the same day, led by CEO Dr. Parmjot Bains and CF&OO McGregor Grant, to discuss the results and address investor inquiries. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited reported a significant increase in US sales for Q4 FY25, achieving a record Total Contract Value of A$6.3 million. This growth, attributed to new leadership initiatives and strategic partnerships like the one with Legacy Health, has enabled the company to qualify for an additional US$5 million in funding from SWK Funding LLC. The funds will support ImpediMed’s growth and commercialization efforts, positioning the company for long-term success and shareholder value creation.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced the cessation of certain securities, specifically 4,667,613 options and 413,284 performance rights, due to the lapse of conditional rights that were not met or became incapable of being satisfied. This cessation reflects a change in the company’s issued capital and may impact stakeholders by altering the company’s financial structure and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has announced a change in its registered and principal business address to Suite 31C, 12-18 Tryon Road, Lindfield, NSW, 2070, effective immediately. This change is part of the company’s ongoing operational adjustments and does not affect its contact number, signaling a seamless transition for stakeholders.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited announced a change in the director’s interest notice, specifically regarding Ms. Christine Emmanuel-Donnelly’s holdings. The change involved an acquisition of 306,446 ordinary shares in the Donnelly Superannuation Fund, increasing her total holdings in this fund to 1,736,255 shares. This transaction, conducted as an on-market trade, reflects the director’s increased investment in the company, potentially signaling confidence in Impedimed’s future prospects and stability.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.